37 results about "Immunoglobulin region" patented technology

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention relates to the field of antibody proteins, in particular to an immunoglobulin Fc dimer with a stable disulfide bond, an Fc fusion protein containing the Fc protein dimer and a calculation design method of the Fc fusion protein. The immunoglobulin Fc protein dimer comprises two protein subunits, a CH3 structural domain of each subunit contains at least one cysteine mutation, and the two protein subunits are combined through an interchain disulfide bond formed by mutation cysteine. Cysteine mutation is specifically introduced into the CH3 structural domain of the Fc region of the immunoglobulin to form a stable interchain disulfide bond, so that the problem of insufficient stability of the Fc protein dimer is solved.

The present invention relates to a multispecific antibody comprising one or two binding domains, which specifically bind to IL-4R (IL4R-BDs), and one or two binding domains, which specifically bind to IL-31 (IL31-BDs), wherein the multispecific antibody comprises an immunoglobulin Fc region. The present invention further relates to nucleic acids encoding said multispecific antibody, vector(s) comprising said nucleic acids, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Provided are an immunoglobulin Fc region-based heterodimeric Fc stent, a heterologous multimeric protein containing the heterodimeric Fc stent, in particular a single or multispecific binding protein, and a composition comprising same and a use.

The present invention relates to a fusion protein comprising GLP-1, immunoglobulin Fc region, and IGF-1, and use thereof. The fusion protein of the present invention has excellent efficiency in blood-brain barrier permeability, and thus can be widely used for the effective treatment of neurological diseases.

The invention provides a preparation method of a recombinant protein for improving retinal oxidative stress. The recombinant protein comprises an immunoglobulin Fc region and a functional structure domain, and the amino acid sequence of the functional structure domain is as shown in SEQ ID NO. 1. The preparation method comprises the following steps: connecting polynucleotide for coding the recombinant protein to an expression vector to construct a recombinant expression vector; and transferring the recombinant expression vector into an expression cell, and carrying out induced expression, separation and purification to obtain the recombinant protein. According to the preparation method, the recombinant protein with high soluble expression and enhanced stability can be obtained.

The present disclosure relates to a novel coronavirus SARS-CoV-2 mutant vaccine and its application, the vaccine comprising a fusion protein comprising: (1) interferon or a functional fragment thereof; (2) novel coronavirus SARS-CoV-2 or a functional fragment thereof; and (3) an immunoglobulin Fc region. The mutant vaccine disclosed herein has long-lasting efficacy, is amenable to industrial production, has activity comparable to that of conventional IFN, has higher immunogenicity and neutralizing antibody titers, and can increase defense against mutant strains. It can be used as a new generation of mutant vaccine drugs to combat the spread of the COVID-19 pandemic.

A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed.

Provided herein are methods for treating or preventing leukemia and myelodysplasia disorders comprising a multifunctional binding protein comprising a first antigen-binding domain and a second antigen-binding domain and all or part of an immunoglobulin Fc region or variant thereof wherein the first antigen-binding domain specifically binds to CD123, and the second antigen-binding domain specifically binds to CD123, and all or part of an immunoglobulin Fc region or variant thereof. And the second antigen-binding domain specifically binds to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-gamma receptor.

The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

The present application relates to a fusion protein and use thereof. The fusion protein comprises a human GLP-1 polypeptide variant and an immunoglobulin Fc region, wherein an amino acid sequence of the human GLP-1 polypeptide variant comprises at least 2 amino acid mutations compared with an amino acid sequence set forth in SEQ ID NO: 2, and the at least 2 amino acid mutations are located at amino acid positions selected from the group consisting of W31, K26, and Y19. The present application also provides use of the fusion protein in treating a disease or a condition.

Provided are PD-1 polypeptide variants including an extracellular domain that binds specifically to PD-L1, and a transmembrane domain or a fragment thereof. The disclosure also provides PD-1 Fc fusion proteins including an immunoglobulin Fc region, and a PD-1 polypeptide variant.

Provided is an adapter comprising an antibody binding domain (AbBD) that specifically binds and crosslinks to an immunoglobulin Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, G32, Q35, S36, N46, G49, E50, K53 or L54 of SEQ ID NO: 1 or combinations thereof, and where the AbBD is photoreactive. Also provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region and / or to an immunoglobulin M (IgM) Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, E50, or L54 of SEQ ID NO: 1 or combinations thereof, where the AbBD is photoreactive. Provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region, where the AbBD is a variant of a Protein L C* domain and has an amino acid replacement / modification at G22 or T46 of SEQ ID NO: 2 or a combination thereof, wherein the AbBD is photo-reactive. Methods for using the AbBD for imaging, diagnosing and / or treating a disease are provided.

The present invention relates to a pharmaceutical composition comprising a protein complex, and its pharmaceutical applications for treating or preventing conditions characterized by impaired leukocyte production, such as neutropenia. The protein complex can also be formed by linking an immunoglobulin Fc region to a bioactive polypeptide via a non-peptide polymer linked to the immunoglobulin Fc region. [Solution] The present invention provides a method for treating chemotherapy-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient, and a method for treating radiation-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient.

The present invention relates to a fusion protein comprising a CXCL14 sequence linked to an immunoglobulin Fc region sequence, methods for preparation thereof, and methods for using it for treating cancer or metabolic syndrome diseases.

The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

The present invention relates to: a cosmetic composition for improving skin condition, a cosmetic composition for strengthening skin barrier, a pharmaceutical composition for preventing or treating atopic dermatitis, and a quasi-drug composition for preventing or ameliorating atopic dermatitis, each composition comprising, as active ingredient, a fusion protein comprising a CD300c protein or a fragment thereof and an immunoglobulin Fc region; and a method for treating atopic dermatitis by using the pharmaceutical composition. The compositions of the present invention have excellent effects of alleviating skin inflammation, reducing dead skin cells, strengthening skin barrier, alleviating xeroderma, and alleviating atopic dermatitis, and thus can be used as an effective therapeutic agent for atopic dermatitis.

A hepatocyte culture method for culturing hepatocytes using a liquid medium and a substrate on which a fusion protein of E-cadherin and an Fc region of an immunoglobulin is immobilized, the hepatocyte culture method being characterized by the application of a flow velocity to the liquid medium.

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

A method of preparing a protein conjugate contains linking a mono-PEGylated immunoglobulin Fc region to a dual agonist exhibiting activity on both glucagon-like peptide-1 (GLP-1) and glucagon. The mono-PEGylated immunoglobulin Fc region is prepared by linking a linker of Formula 1 to the N-terminus of an immunoglobulin Fc region comprising a hinge sequence:CHO-L1-(OCH2CH2)nO-L2-R  [Formula 1].

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

Provided are proteins comprising a variant IgG Fc region, wherein the proteins exhibit significantly reduced binding to human FcγRI when compared with a reference protein comprising the amino acid substitutions L234A / L235A / P329G. Also provided are compositions, methods of treatment and methods to reduce Fc-induced effector functions in a parent protein.

The invention provides a recombinant protein for improving retinal oxidative stress, which comprises an immunoglobulin Fc region and a functional structure domain, and the amino terminal of the functional structure domain is connected with the carboxyl terminal of the immunoglobulin Fc region; wherein the amino acid sequence of the functional structure domain is as shown in SEQ ID NO. 1. The invention also provides a coding nucleic acid of the recombinant protein, an expression vector, a host cell, a pharmaceutical composition containing the recombinant protein and application of the pharmaceutical composition. The recombinant protein can remarkably reverse retinal cell injury caused by oxidative stress, and shows a strong protection or treatment effect.

Provided are a single domain antibody capable of binding to an immunoglobulin Fc region, an immunoglobulin Fc region binding protein comprising the one or more single domain antibodies, and a fusion protein comprising the single domain antibody and an Fc region.

To provide a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis, as well as uses and methods thereof.SOLUTION: A fusion protein comprising, as an active ingredient, a fibroblast growth factor 21 (FGF21) mutant protein; and a pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis, the composition comprising an Fc region of an immunoglobulin.SELECTED DRAWING: Figure 13A

The application discloses a VirusTAC platform for targeted degradation of tumor cell membrane protein EGFR and psoriasis extracellular pathogenic factor IL17A and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an immunoglobulin Fc region, the Fc regions corresponding to the first polypeptide chain and the second polypeptide chain are associated by heterodimerization mutation; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain EGFR antibody or IL17A antibody. The platform realizes precise degradation of tumor-related membrane proteins and extracellular proteins by constructing a chimera of a natural ligand and a targeting antibody, and by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4.

Fc variants are described that comprise one or more amino acid mutations that increase the stability of the Fc variant compared to a parent Fc that does not contain the one or more amino acid mutations, as well as polypeptides comprising the Fc variants and polynucleotides encoding the Fc variants.